Standard of Care sensibility: Oxaliplatin = no.
HCT 116 cells
Human HCT 116 cells were isolated from the colon of a patient with colorectal carcinoma.
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing HCT116 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the HCT 116 cells as xenograft Mean ± SEM (n=5; take rate 100%)
Antineo can also perform an intra-caecal implantation.
Standard-Of-Care Drug Responses
oxylaplatin 5 mg/kg qw → No response
Figure 2: (View PDF)
Effect of oxliplatin treatment on HCT 116 tumour growth Mean ± SEM (n=5 per group; take rate 100%)